Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC)...

treatment of adults with ALK‑positive advanced NSCLC previously treated with crizotinib. In the United States, it is indicated for the treatment of people with...

implications on the response of the tumour and prognosis of the patient. Crizotinib (also a ROS1 and c-MET inhibitor) was approved in Aug 2011 by the US FDA...

include velpatasvir/sofosbuvir, sofosbuvir/daclatasvir, osimertinib, crizotinib, daclatasvir, sofosbuvir, afatinib, axitinib, brigatinib, baricitinib...

positive non-small cell lung cancer. Treatment with crizotinib achieves 60% response rate. However, crizotinib showed no improvement on overall survival compared...

been increasing. Recently, the small molecule tyrosine kinase inhibitor, crizotinib, was approved for the treatment of patients with metastatic NSCLC whose...

responses to crizotinib while 1 patient previously treated with a corticosteroid, prednisone, continued to have progressive disease on crizotinib; and 3) 6...

patients. Crizotinib, which gained FDA approval in August 2011, is an inhibitor of several kinases, specifically ALK, ROS1, and MET. Crizotinib has been...

Previously, it was only indicated for patients who had developed resistant to crizotinib, another ALK inhibitor, but has since had its usage expanded to serve...

in hyperactive ALK protein, which can be treated with ALK inhibitors crizotinib, or its successors alectinib, brigatinib, and ceritinib. Those treated...